search
CAR T cell therapy
Trends
- 1CAR T cell therapy shows two years free of lupus flares●Two years later, CAR T cell therapy shows promise for life without lupus flares
Researchers at UMass Chan Medical School report that lupus patients treated with CAR T cell therapy have remained free of disease flares two years after receiving the one-time cell-based treatment. The therapy, originally developed for blood cancers, reprograms a patient's own immune cells, and the latest follow-up data suggest it may offer lasting remission in autoimmune disease.
- 2UConn Health Launches CAR-T Cell Therapy Program▼UConn Health Launches Cutting-Edge CAR-T Cell Therapy Program
UConn Health has announced the launch of a new CAR-T cell therapy program, a form of immunotherapy that engineers a patient's own immune cells to fight cancer. The initiative brings an advanced, personalised cancer treatment to the Connecticut institution, expanding access for patients in the region who previously had to travel elsewhere for such therapy.
- 3Vyriad Launches First-in-Human Trial of CAR T Therapy VV169▼Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
Biotech company Vyriad has begun the first-in-human clinical trial of VV169, an in vivo CAR T therapy that engineers immune cells inside the patient's body rather than in a lab. The early-stage trial marks a first step in testing the safety of the experimental cancer treatment in people, an approach watched closely as it could simplify a cell therapy process that is currently complex and costly.
- 4Anitocabtagene autoleucel shows sustained response in multiple myeloma▼Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
Anitocabtagene autoleucel, a cell therapy, is associated with sustained clinical responses in patients with heavily pretreated multiple myeloma, according to a report in medical news. The finding is notable for a disease where patients who have exhausted standard lines of treatment typically face poor outcomes. Clinicians are watching whether such CAR-T approaches can extend durable remissions.